All News
ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment
On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.
Read Article
Predicting Cardiovascular Events in SLE
A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.
Read Article
No Special Heart Risk With JAK Inhibitors, Study Finds
Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.
Read Article
Rheumatoid Arthritis Patients Need to Quit Smoking ASAP
While it is known that smoking ups the risk of developing RA, its effect on outcomes in those with established rheumatoid arthritis (RA) is less known. A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.
Read Article
NSAIDs Linked to Heart Failure in Diabetes Patients
Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a first-time hospitalisation for heart failure in patients with type 2 diabetes, according to research presented at ESC Congress 2022.
Read Article
Heavy Metal Rheumatology (9.23.2022)
Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.
Read Article
Clinical Profiles Seen with NXP-2 Antibodies
A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.
Read Article
Gout Comes With Increased Heart Risk
Incidence of acute coronary syndrome (ACS) was significantly higher among gout patients than in the general Swedish population, researchers found, even when data were adjusted for common comorbidities.
Read Article
Pirfenidone Potential in RA-Related Lung Disease
Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial, researchers reported here and in a simultaneous journal publication.
Read Article
Study Reassures on HCQ Heart Risks in Rheumatoid Arthritis
Among U.S. veterans receiving hydroxychloroquine (HCQ) as long-term therapy for rheumatoid arthritis, development of long QT syndrome was rare and not markedly more common compared with similar patients treated with other agents, researchers said.
Read Article
Goofy But True
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.
Read Article
EULAR/ACR Classification in MDA5+ Myositis Patients
The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM
Read Article
Autoimmune Disease Augments Cardiovascular Risk
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
Read Article
Rituximab Efficacy in Systemic Sclerosis
The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.
Read Article
Links:
Links:
Links:
Links:
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/rcnTPkDTjq https://t.co/RbW1fPSjfU
Links:
